Abstract:Abstract Background: Erosive esophagitis (EE) is a gastroesophageal reflux disease characterized by mucosal breaks in the esophagus. Proton pump inhibitors are widely used as maintenance therapy for EE, but many patients still relapse. In this trial, we evaluated the noninferiority of vonoprazan vs. lansoprazole as maintenance therapy in patients with healed EE. Methods: We performed a double-blind, double-dummy, multicenter, phase 3 clinical trial among non-Japanese Asian adults with endoscopically confirmed healed EE from April 2015 to February 2019. Patients from China, South Korea, and Malaysia were randomized to vonoprazan 10 mg or 20 mg once daily or lansoprazole 15 mg once daily for 24 weeks. The primary endpoint was endoscopically confirmed EE recurrence rate over 24 weeks with a noninferiority margin of 10% using a two-sided 95% confidence interval (CI). Treatment-emergent adverse events (TEAEs) were recorded. Results: Among 703 patients, EE recurrence was observed in 24/181 (13.3%) and 21/171 (12.3%) patients receiving vonoprazan 10 mg or 20 mg, respectively, and 47/184 (25.5%) patients receiving lansoprazole (differences: –12.3% [95% CI, –20.3% to –4.3%] and –13.3% [95% CI, –21.3% to –5.3%], respectively), meeting the primary endpoint of noninferiority to lansoprazole in preventing EE recurrence at 24 weeks. Evidence of superiority (upper bound of 95% CI <0%) was also observed. At 12 weeks, endoscopically confirmed EE recurrence was observed in 5/18, 2/20, and 7/20 of patients receiving vonoprazan 10 mg, vonoprazan 20 mg, and lansoprazole, respectively. TEAEs were experienced by 66.8% (157/235), 69.0% (156/226), and 65.3% (158/242) of patients receiving vonoprazan 10 mg, vonoprazan 20 mg, and lansoprazole, respectively. The most common TEAE was upper respiratory tract infection in 12.8% (30/235) and 12.8% (29/226) patients in vonoprazan 10 mg and 20 mg groups, respectively and 8.7% (21/242) patients in lansoprazole group. Conclusion: Vonoprazan maintenance therapy was well-tolerated and noninferior to lansoprazole for preventing EE recurrence in Asian patients with healed EE. Trial Registration: https://clinicaltrials.gov; NCT02388737.

S655 Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease

Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Survey of nocturnal reflux in patients with gastroesophageal reflux disease in China.

Vonoprazan as a Long-Term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-Label Study

Comparison of efficacy of daily and alternate day maintenance treatment of GERD with Vonoprazan 10-mg using Gastroesophageal Reflux Disease Symptom Assessment Scale

Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial

Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

Efficacy of proton pump inhibitor on nighttime reflux symptoms and associated sleep disturbances in patients with gastroesophageal reflux disease: A real-world study in northern China

Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis

Efficacy of Step‐Down Therapy Using Vonoprazan for Symptomatic Mild Reflux Esophagitis

Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care

The Safety and Efficacy of Peroral Endoscopic Cardial Constriction in Gastroesophageal Reflux Disease

Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials

Sa1268 EFFICACY OF 20-MG VONOPRAZAN (VPZ) ON-DEMAND THERAPY FOR NON-EROSIVE REFLUX DISEASE

Vonoprazan: A systematic review of an alternative to proton pump inhibitors

Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis

Efficacy of Long-Term Maintenance Therapy with 10-Mg Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis

Vonoprazan - a new drug for inhibiting gastric acid secretion